Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors
Nicola Maurea(Cancer Institute (WIA)), Giuseppe Mercuro(University of Cagliari), Giovanna Piscopo(University of Cagliari), Carmela Coppola, Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Gennaro Riccio(Sapienza University of Rome), F. Galletta(University of Cagliari), Paolo Spallarossa(Ospedale Policlinico San Martino), Emanuela Esposito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 74
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Fish Waste: From Problem to Valuable Resource
|Marine Drugs|2021|568
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282